SCHEMBL2019134

SCHEMBL2019134

Cc1cc(-c2cccnc2)cc2c1C(=O)N(CC1CC1)C2

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 9/20 0.47
PIK3CD O00329 1/20 0.46
PIK3CA P42336 1/20 0.46
CYP11B2 P19099 7/20 0.40
CYP11B1 P15538 6/20 0.40
CYP1A2 P05177 5/20 0.39
CYP17A1 P05093 1/20 0.39
CYP19A1 P11511 1/20 0.39
MAOA P21397 1/20 0.38
HTR6 P50406 1/20 0.37
SRD5A1 P18405 1/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C9 P11712 2/20 0.37
MKNK1 Q9BUB5 1/20 0.37
MKNK2 Q9HBH9 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2023776 0.87 CYP11B2 (0.46) PIK3CGCYP11B2CYP11B1CYP1A2CYP17A1
SCHEMBL4324289 0.83 PIK3CG (0.47) PIK3CGCYP11B2CYP11B1CYP1A2CYP17A1
SCHEMBL2027087 0.82 DHPS (0.55) PIK3CGCYP11B2CYP11B1CYP3A4CYP2C9
SCHEMBL4331807 0.82 PIK3CG (0.58) PIK3CGCYP11B2CYP11B1CYP1A2CYP17A1
SCHEMBL8231100 0.81 PIK3CG (0.46) PIK3CGCYP11B2CYP11B1CYP1A2CYP17A1
SCHEMBL2026834 0.81 DHPS (0.48) PIK3CGCYP11B2CYP11B1CYP1A2CYP17A1
SCHEMBL4323296 0.81 ALDH1A1 (0.52) PIK3CGCYP11B2CYP11B1CYP1A2CYP17A1
SCHEMBL2021227 0.81 HDAC4 (0.44) PIK3CGCYP11B2CYP11B1CYP1A2CYP17A1
SCHEMBL8237562 0.81 PIK3CG (0.44) PIK3CGCYP11B2CYP11B1CYP1A2CYP17A1
SCHEMBL4342336 0.81 CYP11B2 (0.46) PIK3CGCYP11B2CYP11B1CYP1A2CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US claimed
EP-1778634-A1 ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS AstraZeneca AB (SE) 2007-05-02 EP claimed
WO-2006020879-A1 ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2006-02-23 WO claimed
EP-2357169-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators AstraZeneca AB (SE) 2011-08-17 EP disclosed
EP-2357169-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators AstraZeneca AB (SE) 2011-08-17 EP disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
WO-2006020879-A1 ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators GRM1, GRIN1, GRM3 PIK3CG 1735/4885PIK3CD 1029/4885PIK3CA 1203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.